Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.
Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.
复制标题
DOI：
10.21037/jtd.2018.09.106
复制
发表时间：
2018-09
影响因子：
2.5
通讯作者：
S. Nanjo;T. Bivona
中科院分区：
文献类型：
--
作者：
S. Nanjo;T. Bivona
以基因型为导向的治疗已经为携带靶向致癌驱动因子的非小细胞肺癌（NSCLC）患者带来了显著的临床改善（1）。几种可靶向致癌基因的鉴定和耐药机制知识的提高为获得临床样本以评估肿瘤生物学和耐药性演变提供了依据（2）。
Genotype-oriented treatment has led to dramatic clinical improvements for patients with non-small cell lung cancer (NSCLC) harboring a targetable oncogenic driver (1). The identification of several targetable oncogenes and improved knowledge of resistance mechanisms provide rationale for obtaining clinical samples to assess tumor biology and the evolution of drug resistance (2).